Ronquest N, Paret K, Gould I, Barnett CL, Mladsi D. Effects of stakeholder engagement with Icer on cost-effectiveness of new interventions: lessons learned from a critical review of evaluations from 2018 to 2019. Presented at the Virtual ISPOR 2021 Conference; May 2021.
Herring WL, Grant TJ, Mladsi DM. A mathematical model to estimate the health benefits and costs of diabetic retinopathy screening programs. Presented at the 2015 Institute for Operations Research and Management Science Computing Conference; January 12, 2015. Richmond, VA.
Mladsi D. Linking product attributes with a threshold pricing model: how commercial thresholds can inform the drug discovery process. Presented at the 2012 DIA 24th Annual EuroMeeting; March 2012. Copenhagen, Denmark.
Mladsi DM, Redekop K, Goettsch A, Earnshaw SR. Challenges and insights in establishing and communicating the economic value of companion diagnostics. Presented at the 2010 ISPOR 13th Annual European Congress; November 2010. Prague, Czech Republic.
Odom DM, Bennett L, Irish W, Mladsi DM. Statistical methods to handle incomplete longitudinal patient-reported outcomes data in advanced disease stage trials. Presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France.
Mladsi D, de Cambra S, Gilabert-Perramon A, Faulkner EC. Orphan drug funding: a model for personalized medicine? Presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France.
Mladsi DM, Palmer WN, Miller D. Threshold pricing analysis: an economist's contribution to pharmaceutical pricing. Presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece.
Mladsi DM, Irish WD, Copley-Merriman K, Bhandary D. Statistical measures of treatment effects in oncology: what are we missing? Presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece.
Mladsi DM, Juniper MD, Roskell NS, Mitra D, Shannon PR, Wilson AG. The pharmacological management of fibromyalgia syndrome in the UK primary care setting. Presented at the Annual Congress of the European League Against Rheumatism; June 2008. Paris, France.
Mladsi DM. MMA Part D: how has the US market changed? Presented at the Visiongain 4th Annual Pricing and Reimbursement Conference; May 26, 2006. London, UK.
Mladsi DM. Developing health economic models for assessing cost-effectiveness and product value. Presented at the 2006 Health Economics Conference; April 28, 2006. London, UK.
Gregson N, Sparrowhawk K, Mladsi DM. Global pricing and reimbursement strategy: an integrated analytical framework. Presented at the 2005 ISPOR 8th Annual European Congress; November 8, 2005. Florence, Italy.
Johnson FR, Mladsi DM, Sparrowhawk K. Conjoint analysis: application to global pricing and reimbursement strategy. Presented at the 2005 ISPOR 8th Annual European Congress; November 7, 2005. Florence, Italy.
Lucero MA, Mladsi D, Mauskopf J. Communicating the value: developing messages for payers. Presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. Hamburg, Germany.
Ortiz M, Neighbors DM. Collecting evidence of equivalence: implications for economic analyses. Presented at the 2002 ISPOR 7th Annual International Meeting; May 19, 2002. Arlington, VA.
Irish WD, Neighbors DM, Lopez RB. Using propensity scores to adjust for treatment selection bias: review of methods plus an extension for use in studies with three or more treatment groups. Presented at the 2001 ISPOR 4th Annual European Congress; November 11, 2001. Cannes, France.
Neighbors DM, Candrilli SD. Concomitant medication costing using clinical trial data: a case study. Presented at the 2000 ISPOR 5th Annual International Meeting; May 2000. Arlington, VA.
Neighbors DM. Potential for bias when using clinical trial adverse event rates to estimate toxicity costs. Presented at the 1999 ISPOR 2nd Annual European Congress; November 1999. Edinburgh, Scotland.
Neighbors DM, Downs KE. Medical resource use data collection in clinical trials. Presented at the DIA Meeting Session Economic Assessment in Clinical Trials: Design and Analysis; November 1999. Orlando, FL.
Neighbors D. Clinical benefit endpoints in trials for the treatment of non-small cell lung cancer and hormone-refractory prostate cancer. Presented at the Investigator Meeting; 1998. San Diego, CA.
Neighbors D. Pharmacoeconomic endpoints in FUMA3007: a randomized, open-label study comparing a 28-day oral regimen of 5-fluorouracil plus 776c85 to intravenous gemcitabine for the first-line treatment of patients with unresectable advanced adenocarcinoma of the pancreas. Presented at the Investigator Meeting; 1997. Atlanta, GA.
Neighbors D. Collection of medical resource use data in MA1A2001: a randomized trial of panorex plus 5-fu plus levamisole versus 5-fu plus levamisole in patients with surgically resected stage III carcinoma of the colon. Presented at the Investigator Meeting; 1995.
Neighbors D. Development and use of interactive drug value models. Presented at the UNC School of Pharmacy; 1994. Chapel Hill, NC.
Neighbors D, Mauskopf JA. Importance of quality of life and cost-effectiveness studies in new drug development. Presented at the Southeast Regional Meeting of the American Association of Pharmaceutical Scientists; 1994. Research Triangle Park, NC.